Thus far, tumor cell death induced by RIG-I activation has been reported in multiple types of human cancer cells, including pancreatic cancer, prostate cancer, head and neck squamous cell carcinoma, gastric adenocarcinoma, glioblastoma, and breast cancer (Wu et al., 2017; Elion et al., 2018). Here, RIGI is linked to breast carcinoma.